Integrated CRDMO serving global pharma/biotech from drug discovery through commercial manufacturing.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 16 | 18 | 18 | 18 | 18 | 21 | 4.1k | 21 |
| Reserves | 778 | 850 | 873 | 895 | 993 | 2.1k | 54.1k | 2.5k |
| Borrowings | 304 | 637 | 752 | 869 | 868 | 287 | 33.7k | 223 |
| Other Liabilities | 291 | 312 | 464 | 349 | 361 | 682 | 42.2k | 872 |
| Total Liabilities | 1.4k | 1.8k | 2.1k | 2.1k | 2.2k | 3.1k | 134.2k | 3.6k |
| AssetsFixed Assets | 617 | 659 | 701 | 923 | 1.1k | 1.4k | 72.4k | 1.7k |
| CWIP | 79 | 236 | 345 | 151 | 107 | 124 | 8.8k | 270 |
| Investments | 22 | 63 | 64 | 80 | 80 | 114 | 4.1k | 163 |
| Other Assets | 671 | 858 | 996 | 977 | 979 | 1.5k | 48.8k | 1.5k |
| Total Assets | 1.4k | 1.8k | 2.1k | 2.1k | 2.2k | 3.1k | 134.2k | 3.6k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 127 | 109 | -26 | 88 | 221 | 251 | 330 | 495 |
| Cash from Investing | -158 | -259 | -279 | -95 | -111 | -190 | -565 | -393 |
| Cash from Financing | 268 | -1 | 304 | 81 | -190 | -85 | 314 | -109 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -30 | -139 | -267 | -109 | 156 | 72 | -33 | -94 |
| FCF Margin | — | — | — | — | — | — | — | — |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
SAILIFE · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.